SEHK:2142Biotechs
Assessing HBM Holdings (SEHK:2142) Valuation After Strong 2025 Results And HBM9378 Clinical Advances
HBM Holdings (SEHK:2142) has drawn fresh investor attention after reporting full year 2025 earnings, with sales of US$157.98 million and net income of US$91.33 million, alongside clinical and licensing progress for HBM9378.
See our latest analysis for HBM Holdings.
The recent earnings release and clinical updates appear to have coincided with a strong 7 day share price return of 14.48% and a 30 day share price return of 23.89%, building on a 1 year total shareholder return of 91.66% and a...